TerminatedPhase 1
A Study of WVT078 in Patients With Multiple Myeloma (MM)
Key facts
- Who runs it
- Novartis Pharmaceuticals
- Where
- Atlanta, Madison, and Milwaukee, United StatesSee the 3 sitesAlso in 7 other countries, 9 sites
- Trial code
- Status
- Terminated
- Phase
- Phase 1
- People taking part
- 56 people enrolled
- Started
- 5 Dec 2019
- Ended
- 2 Dec 2024
- Type of study
- Interventional, 2 groups
- Treatments tested
- WVT078
- WHG626
- Record updated
- 24 December 2025
- Why it stopped
- The decision was made for business reasons and was not based on any safety or tolerability concerns
Who can take part
- Age
- 18 years to 99 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Subjects who are relapsed and/or refractory to two or more regimens including an IMID, proteasome inhibitor, and an anti-CD38 agent (if available)
Who cannot take part
- Use of systemic chronic steroid therapy (>or= 10mg/day prednisone or equivalent) or any immunosuppressive therapy within 7 days of first dose of study treatment
- Treatment with cytotoxic or small molecule antineoplastics or any experimental therapy within 14 days or 5 half-lives whichever is shorter
- Malignant disease other than being treated on this study
- Active known or suspected autoimmune disease
- Impaired cardiac function or clinically significant cardiac disease
- Active central nervous system involvement by malignancy or presence of symptomatic CNS metasteses
Where in United States
Also in 7 other countries, 9 sites
- Emory University School of Medicine-Winship Cancer InstituteAtlanta, United StatesNo longer taking part
- University of WisconsinMadison, United StatesNo longer taking part
- Medical College of WisconsinMilwaukee, United StatesNo longer taking part
About the trial
What the trial wants to find out
The design of a phase I, open-label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent WVT078 alone and in combination with WHG626 in patients relapses and/or refractory Multiple Myeloma (MM)
The 2 groups in the trial
- WVT078 in Multiple Myeloma (MM) patientsTreatment being tested
Dose escalation study to determine Maximum Tolerated Dose (MTD)/ Recommended Dose (RD) in adult patients with relapsed and/or refractory Multiple Myeloma (MM)
Treatment: WVT078
- WVT078 in combination with WHG626 in Multiple Myeloma (MM) patientsTreatment being tested
Dose escalation study to determine Maximum Tolerated Dose (MTD)/ Recommended Dose (RD) in adult patients with relapsed and/or refractory Multiple Myeloma (MM)
Treatment: WVT078 and WHG626
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase I, Open-label, Multicenter, Study of WVT078 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- Record updated
- 24 December 2025